Allosteric AKT inhibitors as a targeted cancer therapy: Cancer Biology & Therapy: Vol 9, No 7

507

Views

CrossRef citations to date

Altmetric

Abstract

Commentary to:

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

Craig Cherrin, Kathleen Haskell, Bonnie Howell, Raymond Jones, Karen Leander, Ronald Robinson, Aubrey Watkins, Mark Bilodeau, Jacob Hoffman, Philip Sanderson, George Hartman, Elizabeth Mahan, Thomayant Prueksaritanont, Guoqiang Jiang, Qing-Bai She, Neal Rosen, Laura Sepp-Lorenzino, Deborah Defeo-Jones and Hans E. Huber

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Allosteric AKT inhibitors as a targeted cancer therapy

Information for

Open access

Opportunities

Help and information

Allosteric AKT inhibitors as a targeted cancer therapy

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature